



Overview

Preclinical & IND-Enabling Studies, IND

Foundations in Cancer Therapeutics - Commercialization

Diana Shu-Lian Chow, Ph.D., FNAI

Paula & John J Lovoi Endowed Professor
in Drug Discovery and Development

Professor of Pharmaceutics

Director, Institute for Drug Education & Research (IDER)

College of Pharmacy

Professor of Biomedical engineering, College of Engineering

University of Houston

phar33@central.uh.edu



August 14, 2024





Learning Objectives

- ❖ Overall scope of drug product development:
Bench top discovery to FDA product approval
- ❖ Regulatory milestones – IND & NDA
- ❖ IND – Key components
- ❖ IND-enabling preclinical studies
 - ❖ One case
 - ❖ Local resources



Evaluate Pharma

World Preview 2020, Outlook to 2026

Prescription drug sales expected to reach almost **\$1.4 trn in 2026**.

Despite the COVID-19 pandemic causing near-term challenges across the healthcare sector, the industry **demand for innovative and effective therapies** continues to drive long-term growth.





Figure 5: Worldwide Total Prescription Drug Sales (2012-2026)


Source: EvaluatePharma, June 2020



*CAGR: Compound Average Growth Rate
Evaluate Pharma, World Preview 2020, Outlook to 2026

Figure 9: Worldwide Total Pharmaceutical R&D Spend in 2012-2026

Source: EvaluatePharma, June 2020



Evaluate Pharma, World Preview 2020, Outlook to 2026

Evaluate Pharma


World Preview 2022, Outlook to 2028



Evaluate Pharma, World Preview 2022, Outlook to 2028


30% since pre-pandemic. The Nasdaq Biotech Index in July 2022 gently rose past its pre-Covid levels – almost as if the 27-month rollercoaster ride never happened.

Figure 1: Pharma rises steadily as biotech peaks and falls



Evaluate Pharma, World Preview 2022, Outlook to 2028

Figure 5: VC funding stays strong



Note: Funding for pure-play drug developers only.


Source: Evaluate Pharma



Fresh funds are still emerging, too: China's Giming, for instance, in July 2022 pulled in over \$3 billion for

Evaluate Pharma, World Preview 2022, Outlook to 2028

Drug Development Process


from Discovery to Market





• [Pharmaceutical Bioprocessing](#) 1(1):29-50, April 2013

Drug Discovery and Development Timeline



NCE
NME



15 – 30 months
\$5-10 MM USD



FIH




Drug Development Process

from Discovery to Market

Development process is **expensive, risky & time-consuming**


Cost & time depend on complexity, **platforms**, raw materials, analytical methods, & **experience**

Do it right the first time for IND-enabling preclinical studies, including formulation/drug delivery development



Pharmaceutical Development in Preclinical Phase (1-3 yr, \$ 5-10 MM)

- ❖ Scope of work
 - ❖ 1. Bioanalysis: LC-MS/MS, HPLC
 - ❖ 2. Preformulation: Physicochemical properties, Stability, Compatibility; DSC
 - ❖ 3. Formulation Development Strategies
 - ❖ 4. In vitro Assessments and Formulation Optimization
 - ❖ 5. In vivo Preclinical Evaluations in Rodent & Non-rodent Models :
Pharmacokinetics (PK) & Bio-distribution
Proof-of-concept Efficacy, Toxicity



Pivotal Role of PK in Drug Development

Preclinical
(Non-clinical)

Testing

In vitro
PK/PD


Animal
PK/PD

Toxicity

Animal Testing


IND

Clinical (Human) Testing



What is IND?

Investigational New Drug Application



- A request for authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans.
- Such authorization must be secured **prior to interstate shipment and administration** of any new drug or biological product that is not the subject of an approved New Drug Application or Biologics/Product License Application.
- After IND submitted, the molecule **changes in legal status** under the Federal Food, Drug, and Cosmetic Act and becomes a new drug **subject to specific requirements of the drug regulatory system**.



Pre-clinical Development

- Definition(WIKI PEDIA):
 - In drug development, preclinical development, also named **preclinical studies and nonclinical studies**, is a stage of research that begins, **before clinical trials** (testing in humans) can begin, and during which **important feasibility**, iterative testing and **drug safety** data are collected.
 - The **main goals** of pre-clinical studies are to determine the **safe dose for first-in-time-man (FIH, FTIH) study** and **assess a product's safety profile**. Products may include new medical devices, drugs, gene therapy solutions and diagnostic tools.



Preclinical Experiment

- Pre-clinical Development
- **Chemistry, Manufacturing, and Controls (CMC)**
- Pharmacology studies (*in vivo* and *in vitro* studies)
- Toxicology studies (genetic/animal toxicology, toxicokinetic, acute and chronic toxicology)
- Clinical information/ proposed clinical studies to be conducted



What is CMC?

- To appropriately manufacture a pharmaceutical or biologic specific manufacturing processes, product characteristics, and product testing must be defined in order to ensure that the product is safe, effective and consistent between batches.
- These activities are known as **CMC, Chemistry, Manufacturing and Control.**

The ability to consistently produce the same product to meet the same specifications time after time !

Why is there CMC?

- To assure that the quality of the drug meets appropriate standards and is consistent
- To assure that the drug you are using is the drug described on the label
- To assure that the drug sold to the public will have quality attributes similar to those of the drug demonstrated to be safe and effective

CMC helps maintain the connection in quality between the drug used in clinical studies and the marketed drug

Drug used in clinical studies
Safe and effective

Drug marketed to consumers
Commercial product



Critical Elements of CMC

- How and where is the drug made?
- How are raw materials tested and monitored?
- What control procedures are in place to assure product consistency and quality?
- Are quality attributes adequately identified and characterized for the product?
- Are the test methods used to monitor product quality appropriate?
- How long does the product maintain its quality after it is made (shelf life)?



CMC is specific for the products

- *Sterile injectable product* – **sterility and endotoxin concentration**
- *Oral tablet* – **dissolution profile**
- *Controlled release product* – **release profile of active ingredient over time**
- *Soluble powder for drinking water* – **moisture content as powder, solubility in water**
- **Stability** test is required for all products.



Preclinical Experiment

- Pre-clinical development
 - Chemistry, manufacturing, and controls (CMC)
 - **Pharmacology studies (in vivo and in vitro studies)**
 - **Toxicology studies (genetic/animal toxicology, toxicokinetic, acute and chronic toxicology)**
 - Clinical information/ proposed clinical studies to be conducted



Pharmacology Studies

Guidance for Industry

S7A Safety Pharmacology Studies for Human Pharmaceuticals

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)


ICH
July 2001

TABLE OF CONTENTS

I. INTRODUCTION (1).....	1
A. OBJECTIVES OF THE GUIDANCE (1.1).....	1
B. BACKGROUND (1.2).....	1
C. SCOPE OF THE GUIDANCE (1.3).....	2
D. GENERAL PRINCIPLE (1.4).....	2
E. DEFINITION OF SAFETY PHARMACOLOGY (1.5).....	2
II. GUIDANCE (2).....	2
A. OBJECTIVES OF STUDIES (2.1).....	2
B. GENERAL CONSIDERATIONS IN SELECTION AND DESIGN OF SAFETY PHARMACOLOGY STUDIES (2.2).....	3
C. TEST SYSTEMS (2.3).....	3
D. DOSE LEVELS OR CONCENTRATIONS OF TEST SUBSTANCE (2.4).....	5
E. DURATION OF STUDIES (2.5).....	5
F. STUDIES ON METABOLITES, ISOMERS AND FINISHED PRODUCTS (2.6).....	5
G. SAFETY PHARMACOLOGY CORE BATTERY (2.7).....	6
H. FOLLOW-UP AND SUPPLEMENTAL SAFETY PHARMACOLOGY STUDIES (2.8).....	7
I. CONDITIONS UNDER WHICH STUDIES ARE NOT NECESSARY (2.9).....	8
J. TIMING OF SAFETY PHARMACOLOGY STUDIES IN RELATION TO CLINICAL DEVELOPMENT (2.10).....	9
K. APPLICATION OF GOOD LABORATORY PRACTICE (GLP) (2.11).....	9
III. NOTES (3).....	10
IV. REFERENCES (4).....	11

Pharmacology Studies

- Primary pharmacodynamics
- Secondary pharmacodynamics
- Safety pharmacology



<https://www.creative-biolabs.com/drug-discovery/therapeutics/safety-pharmacology.htm>

Primary and Secondary PD

- The primary and secondary PD should be conducted *in vitro*, using animal and human-derived material and *in vivo* using animal models, as **relevant**.
- These studies should include **target interactions** preferably linked to **functional response**, e.g. receptor binding and occupancy, inhibition of enzymes, duration of effect and dose- response relationships.





FIGURE 1-3 Drugs may interact with receptors in several ways. The effects resulting from these interactions are diagrammed in the dose-response curves at the right. Drugs that alter the agonist (A) response may activate the agonist binding site, compete with the agonist (competitive inhibitors, B), or act at separate (allosteric) sites, increasing (C) or decreasing (D) the response to the agonist. Allosteric activators (C) may increase the efficacy of the agonist or its binding affinity. The curve shown reflects an increase in efficacy; an increase in affinity would result in a leftward shift of the curve.

Primary and Secondary PD

- A dose/concentration--response curve of the pharmacological effect(s) should be established with sufficient titration steps to detect significant pharmacological effects with low doses and to identify active substances with U- shaped, bell-shaped or time dependant dose--response curves.

► Dose-Response Curves for the Analgesic and Depressant Effects of Morphine



Safety Pharmacology Studies

- Definition: Studies that investigate the **potential undesirable pharmacodynamic effects** of a substance on physiological functions in relation to **exposure** in the therapeutic range and above.
- Purposes:
 - a. To identify **undesirable pharmacodynamic properties** of a substance that may have relevance to its human safety
 - b. To evaluate **adverse pharmacodynamic and/or pathophysiological effects** of a substance observed in toxicology and/or clinical studies
 - c. To investigate the **mechanism** of the adverse pharmacodynamic effects observed and/or suspected. The investigational plan to meet these objectives should be clearly identified and delineated.

Safety Pharmacology Studies (Cont'd)

- ***Ex vivo* and *in vitro* systems:** isolated organs and tissues, cell cultures, cellular fragments, subcellular organelles, receptors, ion channels, transporters and enzymes, can be used in supportive studies (e.g., to obtain a profile of the activity of the substance or to investigate the mechanism of effects observed *in vivo*).
- **For *in vivo* studies**, it is preferable to use unanesthetized animals. Data from unrestrained animals that are chronically instrumented for telemetry, data gathered using other suitable instrumentation methods for conscious animals, or data from animals conditioned to the laboratory environment are preferable to data from restrained or unconditioned animals. In the use of unanesthetized animals, the avoidance of discomfort or pain is a foremost consideration.



Safety Pharmacology Studies (Cont'd)

- The core battery of safety pharmacology studies includes the assessment of effects on **cardiovascular, central nervous and respiratory systems**, and should generally be conducted before human exposure, in accordance with **ICH S7A and S7B**.

Choice of Animal Species

- The choice of species is based on which will give the best correlation to human trials. Differences in the gut, enzyme activity, circulatory system, or other considerations make certain models more appropriate based on the dosage form, site of activity, or noxious metabolites.

Canine



May not be good models for solid oral dosage forms because the characteristic carnivore intestine is underdeveloped compared to the omnivore's, and gastric emptying rates are increased.

Choice of Animal Species (Cont'd)

Rodents



Can not act as models for antibiotic drugs because the resulting alteration to their intestinal flora causes significant adverse effects.

Medical device

Most studies are performed in dogs, pigs and sheep which allow for testing in a similar sized model as that of a human. Some species are used for similarity in specific organs or organ system physiology.

☆ FDA, EMA, and other similar international and regional authorities usually require safety testing in at least two mammalian species, including one non-rodent species, prior to human trials authorization.



Toxicology Studies



- Acute and chronic toxicology
- Toxicokinetic
- Genetic toxicology

Acute Toxicology Testing

- To determine the effect of a **single dose** on a particular animal species.
- In acute toxicological testing, the investigational product is administered at different dose levels, and the effect is **observed for 14 days**.
- All mortalities caused by the investigational product during the experimental period are recorded and morphological, biochemical, pathological, and histological changes in the dead animals are investigated.

LD₅₀



Chronic Toxicity Testing

- Providing inferences about the long-term effect of a test substance in animals, and it may be extrapolated to the human safety of the test substance.
- The test compound is administered over **more than 90 days**, and the animals are observed periodically.
- A satellite group may be included in the study protocol. This group has both a control group and high-dose group.
- During the study period, the animals are observed for normal physiological functions, behavioral variations and alterations in biochemical parameters. At the end of the study, tissues are collected from all parts of the animal and subjected to histological analyses.



Toxicokinetics

- An extension of pharmacokinetics deals with the kinetic patterns of higher doses of chemicals/toxins/xenobiotics, helping study the metabolism and excretion pattern of xenobiotics.
- Animal toxicokinetic data help extrapolate physiologically based pharmacokinetics in humans.
- Carried out in rodents, rabbits, dogs, nonhuman primates and swine using many routes of administration.
- Blood sample: Area under the curve, drug distribution ratio, C_{max}, t_{max}, and other pharmacokinetic parameters.
- Toxicokinetic studies may be performed using *in vitro* cell lines also.



Genetic Toxicity Testing

- To identify gene mutations, chromosome changes, and alterations in the DNA sequencing.
- These tests are usually conducted in various species including whole animals, plants, micro-organisms, and mammalian cells. In the whole animal model, rodents are preferred.
- Genetic toxicity is assessed using the rodent chromosome assay, dominant lethal assay, mouse-specific locus test, micronucleus test, heritable translocation assay, and sister chromatid exchange assay.



Other Toxicity Testing

- Carcinogenicity testing
- Skin sensitization tests
- Repeated dose toxicity testing
- Mutagenicity testing
- Subchronic oral toxicity testing (repeated dose 90-day oral toxicity testing)
- One-generation reproduction toxicity testing
- Two-generation reproduction toxicity studies



Once a lead compound is identified, drug development begins with **preclinical research** to determine **safety** and **efficacy** of the drug

Researchers determine the following characteristics about the drug:

- Absorption, distribution, metabolism, and excretion
- Potential benefits and mechanisms of action
- Optimal dosage, and route of administration
- Side effects/adverse events
- Effects on gender, race, or ethnicity groups
- Interaction with other treatments
- Effectiveness compared to similar drugs

Desirable DMPK Properties of a Candidate Substance Intended for Oral Route Administration

- Good water solubility
- High permeability and low efflux in Caco-2 cells
- Sufficient bioavailability
- Adequate half-life for reasonable dosing frequency in human
- Linear PK
- Elimination not dependent on a single route or on a single metabolizing enzyme; without forming active or reactive metabolites in large amounts and without interacting with metabolizing enzymes in relevant concentrations
- Acceptable safety margin (therapeutic index, preferably higher than 10 times)

- Established PK-PD correlation



BASICS OF ALLOMETRIC SCALING

Allometric (Interspecies) Scaling

An empirically established relationship between physiological variables or pharmacokinetic parameters and body weights of mammals,

in **power equation** $P = a (BW)^b$

Where **P** is the dependent biological variable of interest

a is allometric coefficient

a normalization constant

NOT dimensionless dependent on P and BW

b is allometric exponent, often < 1

Allometric (Interspecies) Scaling (Cont'd)

P as Physiological Variables or Pharmacokinetic Parameters

Physiological variables

Heart rate
Blood flow
Blood volume
Organ size (Brain)
Urine output
Longevity

Pkin parameters

CL
CL_{int}
V
t_{1/2}
AUC
C_{max}
F

Allometric (Interspecies) Scaling (Cont'd)


Power Equation

$$P = a (BW)^b$$

$$\text{Log } P = \text{Log } a + b (\text{Log } BW)$$

BW of mammals, $10^0 - 10^9$ gm

(3 gm, shrew – 6000 kg, elephant,
136,000 kg Blue whale)



Allometric (Interspecies) Scaling (Cont'd)

Applications

Improve and expedite drug selection and development-
Selection of FIH

Widely used to extrapolate PK parameters from **animal to human**, based on the similarity of anatomical, physiological and biochemical variables in mammals

Clinical trial simulation and optimization of phase I dosing strategies for **pediatric** patients, based on PK in adults, and in neonatal and juvenile animal models.

Clinical trial simulation and optimization of phase I dosing strategies for **obese** patients, based on PK in lean patients



Allometric (Interspecies) Scaling Applications (Cont'd)

Predict toxicological endpoints in humans

Select equivalent dosage regimens in humans
Less D, longer τ



Allometric (Interspecies) Scaling (Cont'd) Approaches

1. PK parameters derived in 4 or more species (Compartmental or non-compartmental analysis)
2. Linear regression of $\text{Log } P - \text{Log } BW$ for each parameter, with or without MLP (Maximun Life-Span Potential), brain wt, fu modifications
3. Extrapolate the parameter values to 70 kg



Allometric (Interspecies) Scaling Approaches (Cont'd)

4. Use predicted parameters to predict PK equation for drug disposition in humans
5. The prediction helps to choose dose and serum (plasma) sampling time for FIH (First time in Humans) study
6. Observed PK of FIH study and compare with predicted values

PK Modeling & Simulation Prodrug CZ48 & CPT

Excellent Example


Solving Phase I Clinical Trial Issue by thorough PK knowledge from PK modeling with Preclinical PK profile data

The EHC models were developed based on the knowledge gained from preclinical PK in rats
EHC is the **significant** contributing factor to the accumulation of CPT levels and potentially resulting toxicity **in humans**


PK Modeling & Simulation (Cont'd)

Prodrug CZ48 & CPT

Advantage: Lactone stability



CZ48



CPT

Lactone
form


Carboxylat
e form

at physiological
pH (7.4)


PK Modeling & Simulation (Cont'd)

Prodrug CZ48 & CPT

Sustained Concentrations of CZ48/CPT for up to 6 hr after the oral dose of CZ48



- : IV dose of 1 mg/kg of CZ48 in co-solvents (DMSO: PEG400: EtOH, 2:2:1, v/v/v)
- : PO dose of 10 mg/kg of CZ48 in the same co-solvents




(Xaohui Li's Dissertation at UH, 2004)

PK Modeling & Simulation (Cont'd)

Prodrug CZ48 & CPT

Biliary Excretions of CZ48 and CPT after an IV Dose of CZ48

- IV Dose: 5 mg/kg of CZ48 in co-solvent formulation



- Clearance of a drug in bile (CL_{bile}):



$$CL_{bile} = (\text{Amount of a drug excreted into bile during a time interval}) / (\text{AUC}_{plasma})$$

PK Modeling & Simulation (Cont'd)

Prodrug CZ48 & CPT

Biliary Excretion: IV and PO

- ❖ Doses: 5 mg/kg of CZ48 in co-solvent formulation (IV) or 25 mg/kg of CZ48 in the same formulation (PO)



PK Modeling & Simulation (Cont'd)


Prodrug CZ48 & CPT

Biliary Excretions of CZ48 and CPT

- Biliary secretions of CZ48 and CPT as their **parent** forms
- Biliary clearance (CL_{bile}) of CPT (56.38 ml/hr) > CL_{bile} of CZ48 (0.87 ml/hr)
- Approximately 3 % of the dose recovered in bile as CPT
- Increased biliary secretions of CZ48 and CPT after an **oral** dose, compared to those after an IV dose
- Sustained biliary secretions of CZ48 and CPT for 12 hr post **oral** dose
- **Enterohepatic recycling (EHC)** of CZ48 and CPT was **minor** in **rats**

PK Modeling & Simulation (Cont'd)

Prodrug CZ48 & CPT



Model-A



PK Modeling & Simulation (Cont'd) Prodrug CZ48 & CPT

Phase I Clinical Trial Issues


For screening patients, blood samples were collected up to 48 h time points after a single oral dose.

CZ48 reached steady state after 3 doses

Significant **accumulation of CPT levels** and resulting potential toxicity in humans

PK Modeling & Simulation (Cont'd)



Prodrug CZ48 & CPT



PK Modeling & Simulation (Cont'd)


Prodrug CZ48 & CPT

Simulation Profiles of CPT




PK Modeling & Simulation (Cont'd)


Prodrug CZ48 & CPT



Model-A



Model-B



Model-C



GCC Center for Comprehensive PK/PD & Formulation (CCPF)



- Dong Liang, Ph.D. (TSU)
- Huan Xie, Ph.D. (TSU)
- Diana S-L Chow, Ph.D. FNAI (UH)
- Omonike Olaleye, Ph.D., MPH (TSU)
- Suzanne Tomlinson, Ph.D. (GCC)



FORMULATION DEVELOPMENT

PK/PD CHARACTERIZATION

Pre- and Formulation

1. Drug Characterization

- Solubility
- pKa
- Log P
- Stability

2. Basic Formulation:

- Cosolvent
- Cyclodextrin
- Dispersed systems

3. Advanced Drug Delivery:

- Micro/nanoemulsions
- Liposomes
- Nanoparticles



Pre-clinical PK/PD Evaluations

4. Bioanalysis

- Method development and validation to quantitate concentrations of drug or metabolite in biological matrix
- Identification of unknown metabolites using accurate mass

5. In Vitro Metabolism

- Drug metabolism characterization using tissue microsomes, S9 fraction, and Recombinant enzymes
- Metabolite profiling & identification

6. In Vitro Biopharm Characterization

- Membrane permeability and transporter identification
- Bindings to plasma proteins, albumin or α -glycoprotein

7. In Vivo PK

- PK studies in rats and mice after IV, oral, IP and SC drug administration
- Dose linearity PK studies
- Bioavailability studies
- PK studies on tissue distribution

8. In Vitro/In Vivo PD

- Cell proliferation assay
- Apoptosis assay
- DNA damage assay
- Migration/invasion assays
- Xenograft assay
- Biomarker assays on tumors from xenograft models
- Genetic mouse models for PD assays

9. PK/PD Modeling and Simulation

- Consultation on experimental design
- PK modeling development and simulation
- PD modeling and determination of parameters
- PK/PD modeling




Pre-formulation and Formulation


Pre-formulation characterization:
pKa, pH-solubility profiles, logP



Pion SiriusT3





Nano drug delivery systems (NDDS)



Label	Material			Encapsulation efficiency (%)
	MJC13 (mg)	Egg PC (mg)	Cholesterol (mg)	
A	10	200	0	43.4
B	10	200	10	62.8
C	10	200	20	75.2
D*	10	200	25	78.3
E	10	200	30	74.8
F	10	200	40	67.1


Formulation development




SOTAX CE 7smart USP Apparatus 4




Microfluidics







Zetasizer



Bian et al, Int J Nanomedicine, 8:4521-31, 2013



BIOANALYSIS: LC-MS/MS QUANTITATION OF DRUGS & METABOLITES IN BIOLOGICAL SAMPLES




White L, et al. *J Chromatogr B*, 1033-4:106-11, 2016





In Vitro Drug Metabolism & In Situ Permeability


Glucuronidation rates with rat microsomes



Intestinal absorption and biliary secretion of a celecoxib derivative




Du T, et al. *J Sep Sci*, 43:4414-23, 2020



Pharmacokinetic (PK) & Biodistribution Studies


Jugular vein cannulated, rat PK studies in metabolism cage




Mouse PK studies via tail vein




Mouse Blood PK Profile



Patch tongue distribution study



Gao et al, *Pharmaceutics*. 2021 Apr; 13(4): 574.



In vitro in vivo Pharmacodynamics (PD)

In Vitro PD

- Cell proliferation assay
- Apoptosis assay
- DNA damage assay
- Migration/invasion assays





In Vivo PD

- Xenograft assay
- Biomarker assays on tumors from xenograft models
- Genetic mouse models for PD assays



Treatment Day (Day 0) Day 1 After Treatment Day 16 After Treatment



Chen et al, *Oncotarget*, 9:26556-71, 2018

PK/PD MODELING AND SIMULATION



PK Modeling

Software

- Phoenix Modeling Individual and Pop PK
- GastroPlus PK Analysis and PBPK
- WinNonlin PK Analysis

Project Examples:

- Intranasal Scopolamine PK Analysis
- Irinotecan (CPT-11) PK Analysis
- Co-modeling of Parent Comp'd and Metabolite:






PK Modeling and Simulation

Software

- Phoenix Modeling
- GastroPlus

Project Example:

- Clinical Trail of CZ48 and CPT
- EHC and Simulation:





PD Modeling

Software

- Phoenix Modeling
- GastroPlus
- WinNonlin
- Design Expert Factors Correlation

Project Example:

- Riluzole PD Study in Acute Spinal Cord Injured Patients - Progressive Disease Model





PK/PD Modeling

Software

- Phoenix Modeling
- GastroPlus
- WinNonlin
- Symcyp PKPD and Simulation

Project Example:

- Clinical Statin PK/PD Analysis Post Gastro Bypass Surgery
- Atorvastatin PK/PD Modeling:





Concluding Messages

Development process is **expensive, risky & time-consuming**

Recognize **significance of IND-enabling preclinical studies**

Do it right the first time for IND-enabling preclinical studies

Maximize utilization of local resources

<https://www.gcc-ccpf.com/>





Animal Dosing and Sampling

Metabolic cage



Rat dosing:

- **IV bolus**
 - 5 mL/kg to 20 mL/kg
 - In solution; or o/w emulsion
- **Oral gavage**
 - 10 mL/kg, but < 20 mL/kg
 - In solution, emulsion, suspension
- **Intraperitoneal**
 - 5-10 mL/kg, but < 20 mL/kg
 - In solution, emulsion, suspension

Blood sampling:

- Collect at least 5 plasma half-lives
- IV study, “powers of 2” series, i.e., sample at 2, 4, 8, 16, and 30 (32) min, 1, 2, 4, 8, and 16 hours.
- Oral dosing study, 15 min, 30 min, 1, 2, 4, 8, 24, 48, 72 hours, ensuring the excretion of 95% of the absorbed dose